Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BGB-B2033 Alone or with Tislelizumab ± Bevacizumab in Advanced or Metastatic Solid Tumors
jRCT2051260010Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of BGB-B2033 in hepatocellular carcinoma (HCC), gastric cancer (GC), germ cell tumor (GCT) and 1 more (3 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events, Maximum Tolerated Dose or Maximum Administered Dose of BGB-B2033 and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
BGB-B2033
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)germ cell tumor (GCT)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051260010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260010.